Tessa Buckle

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8608101/publications.pdf

Version: 2024-02-01

98 papers	4,482 citations	101496 36 h-index	110317 64 g-index
100 all docs	100 docs citations	100 times ranked	5308 citing authors

#	Article	IF	Citations
1	c-MET Receptorâ€“Targeted Fluorescence on the Road to Image-Guided Surgery in Penile Squamous Cell Carcinoma Patients. Journal of Nuclear Medicine, 2022, 63, 51-56.	2.8	19
2	Advancing intraoperative magnetic tracing using 3D freehand magnetic particle imaging. International Journal of Computer Assisted Radiology and Surgery, 2022, 17, 211-218.	1.7	17
3	The impact of drainage pathways on the detection of nodal metastases in prostate cancer: a phase II randomized comparison of intratumoral vs intraprostatic tracer injection for sentinel node detection. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1743-1753.	3.3	13
4	Clinical application of fluorescent probes. , 2022, , .		0
5	Feasibility of fluorescence imaging at microdosing using a hybrid PSMA tracer during robot-assisted radical prostatectomy in a large animal model. EJNMMI Research, 2022, 12, 14.	1.1	2
6	Click-on fluorescence detectors: using robotic surgical instruments to characterize molecular tissue aspects. Journal of Robotic Surgery, 2022, , 1.	1.0	2
7	Precision surgery: the role of intra-operative real-time image guidance - outcomes from a multidisciplinary European consensus conference.. American Journal of Nuclear Medicine and Molecular Imaging, 2022, 12, 74-80.	1.0	0
8	Interventional nuclear medicine: â€œclickâ€•chemistry as an in vivo targeting strategy for imaging microspheres and bacteria. Biomaterials Science, 2021, 9, 1683-1690.	2.6	9
9	Cyclodextrin/Adamantane-Mediated Targeting of Inoculated Bacteria in Mice. Bioconjugate Chemistry, 2021, 32, 607-614.	1.8	14
10	Interventional nuclear medicine: a focus on radioguided intervention and surgery. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2021, 65, 4-19.	0.4	6
11	Intraoperative visualization of nerves using a myelin protein-zero specific fluorescent tracer. EJNMMI Research, 2021, 11, 50.	1.1	5
12	Translation of c-Met Targeted Image-Guided Surgery Solutions in Oral Cavity Cancerâ€”Initial Proof of Concept Data. Cancers, 2021, 13, 2674.	1.7	8
13	Image-guided surgery: from classical techniques to novel aspects and approaches. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2021, 65, 187-189.	0.4	1
14	The role of fluorescent and hybrid tracers in radioguided surgery in urogenital malignancies. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2021, 65, 261-270.	0.4	2
15	Pre-clinical development of fluorescent tracers and translation towards clinical application. , 2021, , .		0
16	ATP-binding cassette transporters restrict drug delivery and efficacy against brain tumors even when blood-brain barrier integrity is lost. Cell Reports Medicine, 2021, 2, 100184.	3.3	32
17	Hybrid Tracers Based on Cyanine Backbones Targeting Prostate-Specific Membrane Antigen: Tuning Pharmacokinetic Properties and Exploring Dyeâ€“Protein Interaction. Journal of Nuclear Medicine, 2020, 61, 234-241.	2.8	42
18	Can Intraoperative Fluorescence Imaging Identify All Lesions While the Road Map Created by Preoperative Nuclear Imaging Is Masked?. Journal of Nuclear Medicine, 2020, 61, 834-841.	2.8	24

#	Article	IF	Citations
19	Trending: Radioactive and Fluorescent Bimodal/Hybrid Tracers as Multiplexing Solutions for Surgical Guidance. Journal of Nuclear Medicine, 2020, 61, 13-19.	2.8	62
20	Image-Guided Surgery: Are We Getting the Most Out of Small-Molecule Prostate-Specific-Membrane-Antigen-Targeted Tracers?. Bioconjugate Chemistry, 2020, 31, 375-395.	1.8	38
21	Artificial intelligence and robotics: a combination that is changing the operating room. World Journal of Urology, 2020, 38, 2359-2366.	1.2	60
22	Multi-wavelength fluorescence imaging with a da Vinci Fireflyâ€”a technical look behind the scenes. Journal of Robotic Surgery, 2020, 15, 751-760.	1.0	22
23	Evaluation of asymmetric orthogonal cyanine fluorophores. Dyes and Pigments, 2020, 183, 108712.	2.0	3
24	Fluorescence background quenching as a means to increase Signal to Background ratio - a proof of concept during Nerve Imaging. Theranostics, 2020, 10, 9890-9898.	4.6	10
25	Multi-Wavelength Fluorescence in Image-Guided Surgery, Clinical Feasibility and Future Perspectives. Molecular Imaging, 2020, 19, 153601212096233.	0.7	32
26	DDRE-32. ABC TRANSPORTERS RESTRICT THE BRAIN PENETRATION AND INTRACRANIAL EFFICACY OF ANTICANCER AGENTS EVEN WHEN BLOOD-BRAIN BARRIER INTEGRITY IS LOST. Neuro-Oncology, 2020, 22, ii68-ii68.	0.6	0
27	The value of periprostatic fascia thickness and fascia preservation as prognostic factors of erectile function after nerve-sparing robot-assisted radical prostatectomy. World Journal of Urology, 2019, 37, 309-315.	1.2	5
28	Anatomical localization of radiocolloid tracer deposition affects outcome of sentinel node procedures in prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2558-2568.	3.3	16
29	Click Chemistry in the Design and Production of Hybrid Tracers. ACS Omega, 2019, 4, 12438-12448.	1.6	10
30	High-resolution imaging and single-cell analysis via laser ablation-inductively coupled plasma-mass spectrometry for the determination of membranous receptor expression levels in breast cancer cell lines using receptor-specific hybrid tracers. Analytica Chimica Acta, 2019, 1074, 43-53.	2.6	53
31	A prediction model relating the extent of intraoperative fascia preservation to erectile dysfunction after nerve-sparing robot-assisted radical prostatectomy. Journal of Robotic Surgery, 2019, 13, 455-462.	1.0	10
32	In vivo stability of supramolecular hostâ€“guest complexes monitored by dual-isotope multiplexing in a pre-targeting model of experimental liver radioembolization. Journal of Controlled Release, 2019, 293, 126-134.	4.8	17
33	Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer. Journal of Nuclear Medicine, 2019, 60, 71-78.	2.8	76
34	Tracers for Fluorescence-Guided Surgery: How Elongation of the Polymethine Chain in Cyanine Dyes Alters the Pharmacokinetics of a Dual-Modality c[RGDyK] Tracer. Journal of Nuclear Medicine, 2018, 59, 986-992.	2.8	34
35	The best of both worlds: a hybrid approach for optimal pre- and intraoperative identification of sentinel lymph nodes. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1915-1925.	3.3	131
36	A Supramolecular Approach for Liver Radioembolization. Theranostics, 2018, 8, 2377-2386.	4.6	24

#	Article	IF	Citations
37	Bioorthogonally Applicable Fluorescence Deactivation Strategy for Receptor Kinetics Study and Theranostic Pretargeting Approaches. ChemBioChem, 2018, 19, 1758-1765.	1.3	8
38	Improved Brain Penetration and Antitumor Efficacy of Temozolomide by Inhibition of ABCB1 and ABCG2. Neoplasia, 2018, 20, 710-720.	2.3	84
39	Multispectral Fluorescence Imaging During Robot-assisted Laparoscopic Sentinel Node Biopsy: A First Step Towards a Fluorescence-based Anatomic Roadmap. European Urology, 2017, 72, 110-117.	0.9	51
40	Obtaining control of cell surface functionalizations via Pre-targeting and Supramolecular host guest interactions. Scientific Reports, 2017, 7, 39908.	1.6	24
41	Fluorescent CXCR4 targeting peptide as alternative for antibody staining in Ewing sarcoma. BMC Cancer, 2017, 17, 383.	1.1	5
42	Hybrid Imaging Labels: Providing the Link Between Mass Spectrometry-Based Molecular Pathology and Theranostics. Theranostics, 2017, 7, 624-633.	4.6	12
43	Multispectral fluorescence guided surgery; a feasibility study in a phantom using a clinical-grade laparoscopic camera system. American Journal of Nuclear Medicine and Molecular Imaging, 2017, 7, 138-147.	1.0	14
44	Receptor-Targeted Luminescent Silver Bionanoparticles. European Journal of Inorganic Chemistry, 2016, 2016, 3030-3035.	1.0	4
45	Tailoring Fluorescent Dyes To Optimize a Hybrid RGD-Tracer. Bioconjugate Chemistry, 2016, 27, 1253-1258.	1.8	53
46	Diffusion-weighted-preparation (D-prep) MRI as a future extension of SPECT/CT based surgical planning for sentinel node procedures in the head and neck area?. Oral Oncology, 2016, 60, 48-54.	0.8	11
47	Hybrid surgical guidance based on the integration of radionuclear and optical technologies. British Journal of Radiology, 2016, 89, 20150797.	1.0	33
48	Increased levels of choline metabolites are an early marker of docetaxel treatment response in BRCA1-mutated mouse mammary tumors: an assessment by ex vivo proton magnetic resonance spectroscopy. Journal of Translational Medicine, 2015, 13, 114.	1.8	17
49	Detection of colorectal polyps in humans using an intravenously administered fluorescent peptide targeted against c-Met. Nature Medicine, 2015, 21, 955-961.	15.2	231
50	Development of a Hybrid Tracer for SPECT and Optical Imaging of Bacterial Infections. Bioconjugate Chemistry, 2015, 26, 839-849.	1.8	49
51	Fluorescent Lectins for Local in Vivo Visualization of Peripheral Nerves. Molecules, 2014, 19, 9876-9892.	1.7	14
52	U-SPECT-BioFluo: an integrated radionuclide, bioluminescence, and fluorescence imaging platform. EJNMMI Research, 2014, 4, 56.	1.1	16
53	An activatable, polarity dependent, dual-luminescent imaging agent with a long luminescence lifetime. Chemical Communications, 2014, 50, 9733-9736.	2.2	10
54	Hybrid tracers for sentinel node biopsy. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2014, 58, 193-206.	0.4	37

#	Article	IF	Citations
55	Re: Steven Joniau, Laura Van den Bergh, Evelyne Lerut, et al. Mapping of Pelvic Lymph Node Metastases in Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2012.06.057. European Urology, 2013, 63, e20.	0.9	0
56	Use of a Single Hybrid Imaging Agent for Integration of Target Validation with In Vivo and Ex Vivo Imaging of Mouse Tumor Lesions Resembling Human DCIS. PLoS ONE, 2013, 8, e48324.	1.1	20
57	Relationship Between Intraprostatic Tracer Deposits and Sentinel Lymph Node Mapping in Prostate Cancer Patients. Journal of Nuclear Medicine, 2012, 53, 1026-1033.	2.8	52
58	Comparing the Hybrid Fluorescentâ€“Radioactive Tracer Indocyanine Greenâ€“^{99m}Tc-Nanocolloid with ^{99m}Tc-Nanocolloid for Sentinel Node Identification: A Validation Study Using Lymphoscintigraphy and SPECT/CT. Journal of Nuclear Medicine, 2012, 53, 1034-1040.	2.8	214
59	Image navigation as a means to expand the boundaries of fluorescence-guided surgery. Physics in Medicine and Biology, 2012, 57, 3123-3136.	1.6	78
60	Phosphorescence Imaging of Living Cells with Amino Acid-Functionalized Tris(2-phenylpyridine)iridium(III) Complexes. Inorganic Chemistry, 2012, 51, 2105-2114.	1.9	70
61	Imaging agents for the chemokine receptor 4 (CXCR4). Chemical Society Reviews, 2012, 41, 5239.	18.7	76
62	Multimodal Interventional Molecular Imaging of Tumor Margins and Distant Metastases by Targeting Î±_vÎ²₃ Integrin. ChemBioChem, 2012, 13, 1039-1045.	1.3	33
63	Reply to Karol Polom, Dawid Murawa, Wojciech Polom's Letter to the Editor re: Henk G. van der Poel, Tessa Buckle, Oscar R. Brouwer, Renato A. ValdÃ©s Olmos, Fijs W.B. van Leeuwen. Intraoperative Laparoscopic Fluorescence Guidance to the Sentinel Lymph Node in Prostate Cancer Patients: Clinical Proof of Concept of an Integrated Functional Imaging Approach Using a Multimodal Tracer. Eur Urol 2011;60:826â€“33. European Urology, 2012, 61, e19-e20.	0.9	0
64	Targeted non-covalent self-assembled nanoparticles based on human serum albumin. Biomaterials, 2012, 33, 867-875.	5.7	77
65	Feasibility of Sentinel Node Biopsy in Head and Neck Melanoma Using a Hybrid Radioactive and Fluorescent Tracer. Annals of Surgical Oncology, 2012, 19, 1988-1994.	0.7	112
66	Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP. Investigational New Drugs, 2012, 30, 443-449.	1.2	135
67	Multispectral visualization of surgical safety-margins using fluorescent marker seeds. American Journal of Nuclear Medicine and Molecular Imaging, 2012, 2, 151-62.	1.0	21
68	Non-invasive longitudinal imaging of tumor progression using an (111)indium labeled CXCR4 peptide antagonist. American Journal of Nuclear Medicine and Molecular Imaging, 2012, 2, 99-109.	1.0	23
69	Synthesis and Evaluation of a Bimodal CXCR4 Antagonistic Peptide. Bioconjugate Chemistry, 2011, 22, 859-864.	1.8	59
70	Immunohistochemical Detection of the CXCR4 Expression in Tumor Tissue Using the Fluorescent Peptide Antagonist Ac-TZ14011-FITC. Translational Oncology, 2011, 4, 234-IN3.	1.7	18
71	Hybrid Peptide Dendrimers for Imaging of Chemokine Receptor 4 (CXCR4) Expression. Molecular Pharmaceutics, 2011, 8, 2444-2453.	2.3	46
72	Intraoperative Laparoscopic Fluorescence Guidance to the Sentinel Lymph Node in Prostate Cancer Patients: Clinical Proof of Concept of an Integrated Functional Imaging Approach Using a Multimodal Tracer. European Urology, 2011, 60, 826-833.	0.9	295

#	Article	IF	Citations
73	Paclitaxel in self-micro emulsifying formulations: oral bioavailability study in mice. Investigational New Drugs, 2011, 29, 768-776.	1.2	20
74	Questioning the value of 99mTc-HYNIC-annexin V based response monitoring after docetaxel treatment in a mouse model for hereditary breast cancer. Applied Radiation and Isotopes, 2011, 69, 656-662.	0.7	16
75	Tracer-cocktail injections for combined pre- and intraoperative multimodal imaging of lymph nodes in a spontaneous mouse prostate tumor model. Journal of Biomedical Optics, 2011, 16, 016004.	1.4	70
76	Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice. Investigational New Drugs, 2010, 28, 145-155.	1.2	12
77	Dual-emissive quantum dots for multispectral intraoperative fluorescence imaging. Biomaterials, 2010, 31, 6823-6832.	5.7	38
78	Potential value of color-coded dynamic breast-specific gamma-imaging; comparing 99mTc-(V)-DMSA, 99mTc-MIBI, and 99mTc-HDP in a mouse mammary tumor model. Applied Radiation and Isotopes, 2010, 68, 2117-2124.	0.7	6
79	Tumor bracketing and safety margin estimation using multimodal marker seeds: a proof of concept. Journal of Biomedical Optics, 2010, 15, 056021.	1.4	20
80	Validation of intratracheal instillation of lung tumour cells in mice using single photon emission computed tomography/computed tomography imaging. Laboratory Animals, 2010, 44, 40-45.	0.5	18
81	Rapid and Robust Transgenic High-Grade Glioma Mouse Models for Therapy Intervention Studies. Clinical Cancer Research, 2010, 16, 3431-3441.	3.2	52
82	(Non-targeted) radioactive/fluorescent nanoparticles and their potential in combined pre- and intraoperative imaging during sentinel lymph node resection. Nanotechnology, 2010, 21, 482001.	1.3	45
83	A self-assembled multimodal complex for combined pre- and intraoperative imaging of the sentinel lymph node. Nanotechnology, 2010, 21, 355101.	1.3	85
84	Differential effects of anticoagulants on tumor development of mouse cancer cell lines B16, K1735 and CT26 in lung. Clinical and Experimental Metastasis, 2009, 26, 171-178.	1.7	28
85	The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib. Investigational New Drugs, 2009, 27, 31-40.	1.2	132
86	Noninvasive functional imaging of P-glycoprotein-mediated doxorubicin resistance in a mouse model of hereditary breast cancer to predict response, and assign P-gp inhibitor sensitivity. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 406-412.	3.3	19
87	Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition inin vitroandin vivopharmacokinetic studies employing Bcrp1â^'/â^'/Mdr1a/1bâ^'/â^' (triple-knockout) and wild-type mice. Molecular Cancer Therapeutics, 2008, 7, 2280-2287.	1.9	183
88	P-Glycoprotein and Breast Cancer Resistance Protein: Two Dominant Transporters Working Together in Limiting the Brain Penetration of Topotecan. Clinical Cancer Research, 2007, 13, 6440-6449.	3.2	252
89	Validity of bioluminescence measurements for noninvasive in vivo imaging of tumor load in small animals. BioTechniques, 2007, 43, S7-S13, S30.	0.8	121
90	Determination of topotecan in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography. Biomedical Chromatography, 2007, 21, 1191-1200.	0.8	20

#	Article	IF	Citations
91	Bmi1 Controls Tumor Development in an Ink4a/Arf-Independent Manner in a Mouse Model for Glioma. Cancer Cell, 2007, 12, 328-341.	7.7	264
92	Trabectedin (ET-743, Yondelisâ„¢) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype. Investigational New Drugs, 2007, 25, 1-7.	1.2	18
93	Development of luciferase tagged brain tumour models in mice for chemotherapy intervention studies. European Journal of Cancer, 2006, 42, 3294-3303.	1.3	59
94	The effect of P-glycoprotein and cytochrome P450 3a on the oral bioavailability of vinorelbine in mice. Cancer Chemotherapy and Pharmacology, 2006, 57, 819-825.	1.1	10
95	Cannulation of the jugular vein in mice. Laboratory Animals, 2005, 39, 130-132.	0.5	1
96	Cannulation of the jugular vein in mice: a method for serial withdrawal of blood samples. Laboratory Animals, 2003, 37, 181-187.	0.5	37
97	P-glycoprotein and Mrp1 collectively protect the bone marrow from vincristine-induced toxicity in vivo. British Journal of Cancer, 2003, 89, 1776-1782.	2.9	39
98	Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Research, 2002, 62, 6158-64.	0.4	116